Job Announcement: Government Affairs Manager

Job Announcement: We are seeking a Government Affairs Manager to advocate for our policy goals to end the HIV & hepatitis epidemics and to increase healthcare access & affordability, with a focus on prescription drugs. The Government Affairs Manager will be responsible for advocating policy positions before Congress, federal agencies, and state officials, focusing particularly on securing adequate appropriations for domestic HIV and hepatitis prevention/treatment programs.

U.S. Government Appeals Drug Copay Assistance Court Ruling

"We can’t comprehend why the Biden administration, which has championed access & affordability of prescription drugs for the American people, would appeal this decision. By siding against patients who depend on prescription drugs & with insurers, they are allowing insurers to ‘double bill’ and extract more money from patients & drug manufacturers by implementing copay accumulators. The court’s decision is very clear: copay assistance for prescription drugs without a generic equivalent must now count for patients."

House Proposes to Gut Ending HIV Programs

“While we appreciate the sustained funding for some domestic HIV and hepatitis programs, we are devastated by the proposal to eliminate the Ending the HIV Epidemic initiative,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “We were on a trajectory to end HIV by ensuring all people have access to care and treatment, and prevent new infections through increasing access to PrEP, but now all those efforts will be lost. This bill cannot stand as is.”

25 HIV & Hepatitis Organizations File Amicus Brief to Protect Preventive Services Coverage

The HIV+Hepatitis Policy Institute and 24 other HIV and hepatitis organizations filed an amicus brief in support of the U.S. government in Braidwood Management v. Becerra, the challenge to the ACA’s preventive services coverage requirement, arguing, “A wholesale invalidation of the coverage requirement for USPSTF’s recommendations would strike a critical, unnecessary, and costly blow to the battle to end HIV, hepatitis, and other infectious diseases.”

HIV+Hep releases report detailing funding needed to increase PrEP uptake

The HIV+Hepatitis Policy Institute has released a report modeling the resources needed to fund a national PrEP program to cover the cost of medications, associated labs, and prescriber time for the uninsured along with necessary provider and community outreach to increase uptake, estimating the cost at $521 million for the first year and $6.18 billion over ten years.

Nation Must Do Better in Ensuring Patients Receive Hepatitis C Curative Drugs

"This situation is completely unacceptable. We have a cure for a serious infectious disease, but people who have taken the time to get tested and know they have hepatitis C are not being cured," commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. "The vast majority of these people have health coverage but payers such as private insurers, state Medicaid programs, and Medicare are erecting barriers to patient access."

Who We Are

Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.

Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.

Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.

Key Issues

Causes We Care About, and So Should You!


Promote necessary funding, programs, and policies to end the HIV epidemic in the United States


Promote necessary funding, programs, and policies to end viral hepatitis in the United States


Promote necessary funding, programs, and policies to end viral hepatitis in the United States

Facebook posts by @HIV+Hep

Tweets by @HIV+Hep

Pin It on Pinterest